Biosimilars have now reached the next and some will say the pivotal plateau: determining interchangeability.
Interchangeability is important because it means a biosimilar can be substituted for a biologic by a pharmacist without the approval of a physician.
“Interchangeable” is a very interesting word because it has no synonym. There’s no other way to say what it means. Determining interchangeability for biosimilars is essential in order for them to realize the cost savings for which patients have been waiting.
To understand why interchangeability is important, it’s necessary to understand the difference between generic and biosimilar drugs.
A generic is an exact copy of a small molecule, chemically-derived drug. It’s exact because it has the same ingredients. Interchangeability for a generic drug is a given: you just follow the recipe.
A biologic is complex, large molecule which is made in living cells by adding a piece of DNA to a cell.You can grow a copy, but it will never be exactly the same. That is why copies of biologics are called biosimilars: they are approved by the FDA, not as exact copies, but as highly similar versions of the original biologic.
The Biologic Price Competition and Innovation Act (BPCIA), which is part of the Affordable Care Act, created an abbreviated pathway for the FDA to approve biosimilars of a biologic just as the Hatch-Waxman Act created such a pathway for generic drugs. But interchangeability can’t be assumed for biosimilars because it and the original biologic aren’t identical.
The BPCIA allows the FDA, on extra submissions from the biosimilar applicant, to give the biosimilar the additional designation as interchangeable for the original biologic. The FDA has, to date, approved four biosimilars. None has yet been designated as interchangeable.
On Jan. 17, the FDA issued its long-awaited draft guidance for applicants on the recommended submission criteria for an interchangeable biosimilar. I wrote two articles on the draft guidance: the first published the day the draft guidance came out, with immediate reaction from attorneys, and the second a week later with more reactions.
Some commenters were concerned that the draft guidance wasn’t clear enough while others felt it was a good first step that would become better through comments from stakeholders.
Comments on the draft guidance are to be submitted to the FDA by March 20, and Bloomberg BNA will cover what stakeholders in the development of biosimilars have to say about it.
Stay on top of new developments in health law and regulation with a free trial to the Health Law Resource Center.
Learn more about Bloomberg Law and sign up for a free trial.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)